Anisha Apte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anisha Apte has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa E. Vaughn
Laboratory for Fetal and Regenerative Biology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO 80045, USA
1 shared publication - Alyssa San Agustin
Laboratory for Fetal and Regenerative Biology, Department of Surgery, Banner Children’s at Diamond Children’s Medical Center, University of Arizona Tucson College of Medicine, Tucson, AZ 85721, USA
1 shared publication - Bailey D. Lyttle
Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA
1 shared publication - Carlos Zgheib
Laboratory for Fetal and Regenerative Biology, Department of Surgery, College of Medicine, University of Arizona, Tucson, AZ 85721, USA
1 shared publication - David M. Jackson
Ceria Therapeutics, Inc., Tucson, AZ 85721, USA
1 shared publication - Elayaraja Kolanthai
Advanced Materials Processing and Analysis Center, Department of Materials Science and Engineering, Nanoscience Technology Center, Biionix Cluster, College of Medicine, University of Central Florida, Orlando, Florida, USA
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 248
Topical Delivery of CNP-miR146a via a Pluronic Lecithin Organogel Enhances Diabetic Wound Healing
Background: Diabetes mellitus is common and associated with numerous complications including diabetic foot ulcers (DFU), which affect a third of patients and are associated with high morbidity and mortality. There are limited pharmacologic treatment options available with mixed efficacy. We have developed a novel therapeutic targeting inflammation and oxidative stress by conjugating microRNA-146a to cerium oxide nanoparticles to create CNP-miR146a and have found that injectable CNP-miR146a is associated with improved wound healing in a diabetic murine model. We hypothesized that a topical formulation of CNP-miR146a would be associated with equivalent improvements in wound healing. Methods: Release tests of CNP conjugated to fluorescein isothiocyanate were performed to determine the optimal gel base for sustained release. Diabetic (db/db) mice were cutaneously wounded and treated with topical CNP-miR146a, empty gel, injectable CNP-miR146a, or injectable phosphate-buffered saline (PBS). Wound healing over time was compared between groups. Histological samples were collected and analyzed for CD45 and CD31 positivity at multiple timepoints. Results: CNP-miR146a in a topical pluronic lecithin organogel (PLO) base was associated with significantly improved wound healing compared to empty gel or injected PBS and equivalent to injected CNP-miR146a. Treatment with CNP-miR146a was also associated with decreased CD45 positivity and increased CD31 positivity, suggesting decreased inflammation and improved angiogenesis. Conclusions: Topical delivery of CNP-miR46a in a PLO base holds significant promise as a potential therapeutic for DFU and may improve patient compliance due to ease of delivery.
- 17 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 248
Open AccessTopical Delivery of CNP-miR146a via a Pluronic Lecithin Organogel Enhances Diabetic Wound Healing
Background: Diabetes mellitus is common and associated with numerous complications including diabetic foot ulcers (DFU), which affect a third of patients and are associated with high morbidity and mortality. There are limited pharmacologic treatment options available with mixed efficacy. We have developed a novel therapeutic targeting inflammation and oxidative stress by conjugating microRNA-146a to cerium oxide nanoparticles to create CNP-miR146a and have found that injectable CNP-miR146a is associated with improved wound healing in a diabetic murine model. We hypothesized that a topical formulation of CNP-miR146a would be associated with equivalent improvements in wound healing. Methods: Release tests of CNP conjugated to fluorescein isothiocyanate were performed to determine the optimal gel base for sustained release. Diabetic (db/db) mice were cutaneously wounded and treated with topical CNP-miR146a, empty gel, injectable CNP-miR146a, or injectable phosphate-buffered saline (PBS). Wound healing over time was compared between groups. Histological samples were collected and analyzed for CD45 and CD31 positivity at multiple timepoints. Results: CNP-miR146a in a topical pluronic lecithin organogel (PLO) base was associated with significantly improved wound healing compared to empty gel or injected PBS and equivalent to injected CNP-miR146a. Treatment with CNP-miR146a was also associated with decreased CD45 positivity and increased CD31 positivity, suggesting decreased inflammation and improved angiogenesis. Conclusions: Topical delivery of CNP-miR46a in a PLO base holds significant promise as a potential therapeutic for DFU and may improve patient compliance due to ease of delivery.